FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	$D \subset$	20540	
wasnington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	burden									
hours per response	e: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						_	_			_			_					_		
1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Sheridan John F]	TANDEM DIADETES CARE INC INDM									X Dire	ctor		10% Ov	wner	
(Last)	Œ	iret)	(Middle)		2.00	O Data of Frankrich Transportion (1) 11 (5) 11 (7)								-	X Office below	er (give title w)		Other (s	specify	
(Last) (First) (Middle) 12400 HIGH BLUFF DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 05/15/2023										PRESIDENT & CEO				
(Street)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
SAN DI	EGO C.	A !													X Form filed by One Reporting Person					
(City)	(S	tate)	(Zip)											Form filed by More than One Reporting Person						
(Sign) (Signs)						Rule 10b5-1(c) Transaction Indication														
						Check	this b	oox to inc affirmative	dicate the defense	at a tra e cond	ansa ditio	action was ns of Rule	made 10b5-	pursua -1(c). S	ant to a co See Instruc	ontract, instr ction 10.	uction or writte	en plar	n that is intend	ded to
		Tabl	e I - No	n-Deriv	ative \$	Sec	uriti	es Ac	quire	d, D	isp	osed (of, o	r Be	neficia	ally Owr	ed			
			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr				rities Acquired (A) ed Of (D) (Instr. 3, 4			nd Secu Bene Owne	icially d Following	Forn (D) c	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									e \	v	Amount	:	(A) or (D)	Price	Trans	eported ransaction(s) nstr. 3 and 4)			(Instr. 4)	
Common Stock			05/15/	2023				A			560 ⁽¹	1)	A	\$27.	32	.5,539		D		
Common Stock			05/15/	2023				N			793	3	A	\$0		6,332		D		
Common Stock		05/15/	/2023	2023				2)		275	5 D		\$32.	13 16,057			D			
Common Stock 05/1:			05/15/	/2023			N	[8,94						D				
Common	amon Stock 05/15/			/2023	2023			F ⁽⁾	2)		3,094 D \$		\$32.	2.13 21,908		D				
		Ta	able II -	Derivat (e.g., p	tive Se uts, ca	ecui alls,	ritie: , wa	s Acq rrants	uired s, opti	, Dis	spc s, c	sed of onverti	f, or ible	Ben secu	eficiall ırities)	y Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,		ransaction ode (Instr.		on of		6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Se (Instr. 3 and 4		3 Security d 4)	8. Price (Derivativ Security (Instr. 5)		e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	sable		xpiration ate	Title		Amount or Number of Shares					
Restricted Stock Unit	(3)	05/15/2023			M			793	(4)		(4)		nmon ock	793	\$0	6,339)	D	
Restricted Stock	(3)	05/15/2023			м			8 945	(5	1		(5)	Com	nmon	8 9/15	\$0	17.89	1	D	

Explanation of Responses:

- 1. The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 16, 2022 through May 15, 2023. This transaction is also exempt under Rule 16b-3(c).
- 2. Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- 3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan).
- 4. RSU granted on 5/18/2021 vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the 15th day of the month that corresponds to the anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan.
- 5. RSU granted on 5/25/2022 vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on the 15th day of the month that corresponds to the anniversary of the grant date, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter, subject to the terms of the 2013 Plan.

Remarks:

Unit

/s/ Rachel Malina , Attorneyin-Fact for John F. Sheridan

05/17/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.